Computational biology pioneer John Quackenbush watched a lab once humming with discovery go silent. Part 4 of STAT's "American Science, Shattered" series.
At the American Society of Hematology annual meeting, Gilead and Arcellx reported promising data for their multiple myeloma CAR-T therapy anito-cel.
Freenome will hit the public markets by merging with Perceptive Capital Solutions Corp, a SPAC, in a $330 million deal.
The data bolster Incyte's efforts to develop a new type of drug for myelofibrosis, and suggest the treatment may help it replace Jakafi.
